This fact sheet describes the positive impact that adjuvants can have on vaccine efficacy and, potentially, immunization program costs. It also describes PATH’s work to expand global access to proprietary and non-proprietary adjuvants as well as relevant formulations technologies to facilitate their successful exploration and use by product development partnerships and developing-country vaccine manufacturers.
Corporate author(s): PATH
Publication date: June 2012
709 KB PDF
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA